Arrowhead Pharmaceuticals Corp (ARWR) Reports Dosing of 1st Hepatitis B Patient in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV

May 14, 2018 7:34 AM
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first 3 hepatitis B virus (HBV) patients in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


FDA Management Comments

Next Articles